Astellas Hopes For Better In R&D

Japan's third-largest pharmaceutical firm, Astellas, is hoping to reverse a series of setbacks in its research pipeline. The company is aggressively pursuing in-licensing deals for promising new compounds, but has been forced to drop a number of potential candidates despite soaring investment in

To read the full article, please choose one of the following options: